Jame Fine Chemicals, Inc.

Jfc Technologies, LLC

Amoco Corporation

Other

Lonza Group, Ltd.

Gluconova, LLC

Jfct Technologies, LLC

Jfc Technolries, LLC

Vilas M Chopdekar

James R Schleck

Sham N Redkar

Cheng Guo

Markus Matzner

James E Harris

Abe Berger

James Spanswick

Christopher M Burger

Hemant S Desai

Raja G Achari

Amanda J Hall

Vernon A Brown

Sajal Das

Angelo Mellozzi

George J Keyko

Megan B Casey

Michael J Torntore

Dina Donatiello

Michelle Y McGough

Timothy N Truong

Mary P Camaga

James G Schleck

Polyimide oligomers of the general formula:M-(Z&#x2014;Y&#x2014;X&#x2014;Y&#x2014;Z)-Mwherein n is an integer of 1 to 20; X comprises an aromatic diamine containing 2-4 aryl moieties, each of which contains 0-4 substituents; Z is independently the same as X or is a different aromatic diamine containing 1-4 aryl moieties, each of which contains 0-4 substituents; Y comprises an aromatic dianhydride containing 1-4 aryl moieties, each of which contains 0-4 substituents; and M is independently the same as Y or is a substituted or unsubstituted anhydride, a substituted or unsubstituted dianhydride, a substituted or unsubstituted bisimide, or a substituted or unsubstituted monomeric or oligomeric phthalonitrile.

Polyimide oligomers

A salt of a glucosamine base having a purity of at least about 99 wt. % and a maximum halide content of about 0.01 wt. %, and an organic acid. The organic acid that is saltified with the glucosamine base is preferably a hydroxyacid or a ketoacid. Preferably, the salt is stabilized by coating the salt with at least one pharmaceutically acceptable polymer comprising a water-soluble, water-immiscible and/or water-swellable homopolymer and/or copolymer. Suitable polymers include carboxypolymethylene homopolymers and copolymers; polyethylene glycol homopolymers and copolymers; polypropylene glycol homopolymers and copolymers; ethylcellulose; povidone homopolymers and copolymers; polyacrylic acid homopolymers and copolymers; polyacrylamide homopolymers and copolymers; polysaccharides; and mixtures of two or more of the foregoing polymers. The resultant coated salt composition will be stable at ambient temperatures and upon exposure to the atmosphere.

Halide-free glucosamine base-organic acid salt compositions

A stabilized glucosamine base composition comprising a glucosamine base having a purity level of at least 99.0 wt. % and a maximum halide content of about 0.01 wt. % coated with at least one pharmaceutically acceptable polymer comprising a water-soluble, water-immiscible and/or water-swellable homopolymer and/or copolymer. The resultant coated glucosamine base composition will be stable at ambient temperatures and upon exposure to the atmosphere. Suitable polymers include carboxypolymethylene homopolymers and copolymers; polyethylene glycol homopolymers and copolymers; polypropylene glycol homopolymers and copolymers; ethylcellulose; povidone homopolymers and copolymers; polyacrylic acid homopolymers and copolymers; polyacrylamide homopolymers and copolymers; polysaccharides; and mixtures of two or more of the foregoing polymers.

Stabilized halide-free glucosamine base and method of preparation

A complex of glucosamine having a purity of at least about 99 wt. % and a maximum halide content of about 0.01 wt. %, and a therapeutic drug having a pKof less than 7. Preferably, the complex is stabilized by coating it with at least one pharmaceutically acceptable polymer comprising a water-soluble, water-immiscible and/or water-swellable homopolymer and/or copolymer. Suitable polymers include carboxypolymethylene homopolymers and copolymers; polyethylene glycol homopolymers and copolymers, povidone homopolymers and copolymers; polyacrylic acid homopolymers and copolymers; polyacrylamide homopolymers and copolymers; polysaccharides; and mixtures of two or more of the foregoing polymers. The resultant coated complex will be stable upon exposure to ambient temperature and/or the atmosphere. Suitable therapeutic drugs fall into the following classes: &#x3b1;- and &#x3b2;-Adrenergic Agonists; Narcotic and Non-Narcotic Analgesics; Anorexics; Antiallergics; Antianginals; Antiarrhythmics; Antiasthmatics; Antibiotics; Anticoagulants; Anticonvulsants; Antidepressants; Antidiabetics; Antihistaminics; Antihypertensives; Nonsteroidal Anti-Inflammatories; Antimigraines; Antineoplastics; Antiparkinsonians; Antipsychotics; Antipyretics; Antispasmodics; Antithrombotics; Antiulceratives; Anxiolytics; Decongestants; Diuretics; Hepatoprotectants; Sedatives; and Vasodilators.

Halide-free glucosamine-acidic drug complexes

A glucosamine base having a pure level of at least about 99.0 wt. % and a maximum halide content of 0.01 wt. %. The pure glucosamine base is prepared by reacting a glucosamine halide, e.g., glucosamine hydrochloride, with a lithium base in the presence of a C-Calcohol to thereby generate a C-Calcohol solution of a lithium halide and an insoluble halide-free glucosamine base and thereafter separating the insoluble halide-free glucosamine base from the C-Calcohol solution of the lithium halide. Preferably, the lithium base comprises anhydrous lithium hydroxide and the preferable alcohol comprises methanol.

Halide-free glucosamine base and method of preparation

A method for preparing n-acetylglucosamine starting from glucosamine base having a purity level of at least about 99 wt. % and a maximum halide content of about 0.01 wt %. The glucosamine base is slurried in a diluent comprising a C-Cstraight or branched-chain alcohol, e.g., isopropyl alcohol, sec. butyl alcohol, tert. butyl alcohol, etc. Thereafter, an acylating agent, e.g., acetic anhydride, present in at least a stoichiometric amount, is slowly added to the slurry while maintaining the reaction mixture at a temperature below about 20&#xb0; C. The n-acetylglucosamine prepared by the process of the invention will be quite pure, e.g., it will have a purity of at least 98%, as measured by HPLC, a melting point in the range of 196-205&#xb0; C. and a specific rotation, measured at room temperature after standing in water for several hours, of [&#x3b1;]=39-43&#xb0;.

Method for preparing N-acetylglucosamine

Glucosamine phosphate having a purity of at least about 99 wt. %, and a maximum halide content of about 0.01 wt. %. Preferably, the glucosamine phosphate is stabilized by coating it with at least one pharmaceutically acceptable polymer comprising a water-soluble, water-immiscible and/or water-swellable homopolymer and/or copolymer. Suitable polymers include carboxypolymethylene hompolymers and copolymers; polyethylene glycol homopolymers and copolymers; polypropylene glycol homopolymers and copolymers; ethylcellulose; povidone homopolymers and copolymers; polyacrylic acid homopolymers and copolymers; polyacrylamide homopolymers and copolymers; polysaccharides; and mixtures of two or more of the foregoing polymers. The resultant coated glucosamine phosphate composition will be stable at ambient temperatures and upon exposure to the atmosphere.

Halide-free glucosamine phosphate compositions and methods of preparation

Glucosamine sulfate having a purity of at least about 99 wt. %, and a maximum halide content of about 0.01 wt. %. Preferably, the glucosamine sulfate is stabilized by coating it with at least one pharmaceutically acceptable polymer comprising a water-soluble, water-immiscible and/or water-swellable homopolymer and/or copolymer. Suitable polymers include carboxypolymethylene homopolymers and copolymers; polyethylene glycol homopolymers and copolymers; polypropylene glycol homopolymers and copolymers; ethylcellulose; povidone homopolymers and copolymers; polyacrylic acid homopolymers and copolymers; polyacrylamide homopolymers and copolymers; polysaccharides; and mixtures of two or more of the foregoing polymers. The resultant coated glucosamine sulfate composition will be stable at ambient temperatures and upon exposure to the atmosphere.

Halide-free glucosamine sulfate compositions and methods of preparation

The invention pertains to a method for preparing diphenhydramine tannate by reacting diphenhydramine free base at a temperature of about 75 to about 150&#xb0; C. with tannic acid neat or as an aqueous slurry containing up to about 20 wt. % water. The diphenhydramine free base may be obtained by reacting a commercially available diphenhydramine salt such as diphenhydramine maleate with a base such as aqueous sodium hydroxide. The resultant diphenhydramine tannate has extended release properties and is useful in pharmaceutical compositions as an antihistamine for human beings.

Hot melt method for preparing diphenhydramine tannate

The invention pertains to a method for preparing dexchlorpheniramine ('dexchlor') tannate by reacting dexchlorpheniramine free base at a temperature of about 75 to about 150&#xb0; C. with tannic acid neat or as an aqueous slurry containing up to about 20 wt. % water. The dexchlorpheniramine free base may be obtained by reacting a commercially available dexchlorpheniramine salt such as dexchlorpheniramine maleate with a base such as aqueous sodium hydroxide. The resultant dexchlor tannate has extended release properties and is useful in pharmaceutical compositions as an antihistamine for human beings.

Method for preparing dexchlor tannate

The invention pertains to carbinoxamine tannate and to a method for preparing carbinoxamine tannate by reacting carbinoxamine free base at a temperature of about 50 to about 150&#xb0; C. with tannic acid neat or as an aqueous slurry containing about 5 to about 30 wt. % water.

Carbinoxamine tannate

The invention pertains to a method for preparing pseudoephedrine tannate by reacting pseudoephedrine free base at a temperature of about 70 to about 110&deg; C. with tannic acid neat or as an aqueous slurry containing about 5 to about 30 wt. % water.

Process for preparing pseudoephedrine tannate

The invention pertains to a process for preparing guaifenesin tannate. The process involves the steps of mixing guaifenesin with tannic acid in the presence of water, continuing to mix the reaction mixture for about 5 minutes to about 4 hours and thereafter removing at least about 80 wt.% of the water by freeze-drying the reaction mixture.

Process for preparing guaifenesin tannate

The invention pertains to a novel composition comprising guaifenesin tannate and to a method for preparing guaifenesin tannate by reacting guaifenesin with tannic acid at a temperature above the melting point of guaifenesin. The guaifenesin tannate has extended release properties and is useful in pharmaceutical compositions as an expectorant in warm-blooded animals or as a muscle relaxant in non-human animals.

Guaifenesin tannate

The invention pertains to a composition comprising dextromethorphan tannate and to a method for preparing dextromethorphan tannate by reacting dextromethorphan at a temperature of about 80 to about 180&deg; C. with tannic acid either neat or as an aqueous slurry containing about 5 to about 30 wt. % water. The dextromethorphan tannate has extended release properties and is useful in pharmaceutical compositions as an antitussive for human beings.

Growing community of inventors

Edison, NJ, United States of America

Vilas M Chopdekar